• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Dermal Infusions and Injections Lead to Improved Skin Quality


Researchers say tissue biostimulation can lead to consistent improvement in skin evenness and the appearance of pores, wrinkles, and unwanted pigment.

Dermal infusions and injections, a form of tissue biostimulation, can lead to better overall skin quality, including consistent improvements to skin appearance, texture, and cosmetic concerns such as wrinkles or pigment.


In a recent study,1 researchers sought to determine safe, replicable methods of improving topical exosome absorption in order to enhance overall patient skin quality.

“To our knowledge, this is the first publication that shows preservation of the efficacy of exosomes after dermal infusion without breaking the surface of the skin in some manner,” study authors wrote.

Participants (n=40) were men and women ranging from 34 to 72 years old. Of these participants, several underwent different therapies.

Prior to their respective therapies, all participants were documented at baseline using a skin analysis and Quantificare 3-D photography. Before their infusion and/or injection treatments, all participants’ faces were cleansed using a glycolic acid facial wash and exfoliated with sea salt for researchers to induce what is referred to as a “homing inflammatory environment.”

Additionally, researchers applied a nitric oxide-generating serum for absorption, conducted a 3 MHz ultrasound for deepened absorption, applied a topical emulsion, and conducted a cavitating ultrasound for emulsion absorption in all participants, regardless of treatment therapy.

Therapies included:

  • 20 participants were treated using stand-alone exosome biostimulatory infusion
  • 5 participants were given exosome biostimulatory infusion followed by a diluted (1:1) calcium hydroxylapatite (CaHA) facial injection
  • 5 participants received exosome biostimulatory infusion followed by a hyperdiluted (1:4) CaHA neck injection
  • 5 participants were given a diluted (1:1) CaHA facial injection—without exosomes
  • and 5 participants were given a hyperdiluted (1:4) CaHA neck injection—without exosomes

Additionally, all participants were treated with a combination of 660 nm and 930 nm wavelength high-intensity LED therapy.

30 days after treatment, all participants completed a post-treatment Quantificare analysis. 16 of 20 dermal infusion patients reported that they were very satisfied with their results, and 4 of 20 reported being satisfied.

“Uniformly, all Dermal Infusion Patients and CaHA injection patients alone, showed an improvement in the tone, quality, and clarity of their skin with a reduction in fine lines, pores, pigment oiliness, and an improvement in texture and vascularity,” study authors wrote. “The patients who had dermal infusions immediately prior to CaHA injections displayed an earlier and more enhanced response than the CaHA facial injections alone at 30 days.”

Within all treatment groups, researchers noted a lack of any adverse events, allergic reactions, or signs of hypersensitivity.

“An exciting finding in this study is the apparent improved biostimulatory effect of the dilute and hyperdilute CaHA by first ‘priming’ the skin with the exosome/hyaluronic acid/botulinum toxin ‘soup,’” study authors wrote. “Consistent improvement of the Quantificare metrics by 30 days or sooner in the ‘priming’ population suggests a piggyback effect via the combination approach. This warrants further study of this phenomenon.”


  1. Chernoff G. Combining topical dermal infused exosomes with injected calcium hydroxylapatite for enhanced tissue biostimulation. Journ of Cosm Dermatol. 2023;22(S1):15-27. doi:10.1111/jocd.15695
Related Videos
© 2024 MJH Life Sciences

All rights reserved.